High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients

Table 1 Impact of clinicopathological parameters in combination with MACC1 and KRAS mutation status concerning MFS

Covariates	Multivariate MACC1		Multivariate mutated (G12 or G13) KRAS		Multivariate G13 mutated KRAS		Multivariate G12 mutated KRAS
Covariates	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)
Molecular Markers MACC1 (low vs. high) KRAS G12/G13 (wt vs. mutated)	<0.001	6.09 (2.50-14.85)	0.302	1.55 (0.67-3.59)	0.042	5.19 (1.06-25.45)	0.543	1.34 (0.52-3.42)
Age at diagnosis (<60) vs. (>60) years	0.970	1.02 (0.41-2.52)	0.892	0.94 (0.39-2.26)	0.648	1.30 (0.43-3.93)	0.940	1.04 (0.37-2.90)
By gender Male vs. Female	0.890	0.94 (0.41-2.17)	0.969	1.02 (0.44-2.34)	0.494	1.42 (0.52-3.91)	0.963	0.98 (0.41-2.35)
UICC stage (I) vs. (II + III)	0.473	1.65 (0.42-6.53)	0.191	2.42 (0.64-9.09)	0.356	2.16 (0.42-11.10)	0.115	3.59 (0.73-17.54)
By grading (G1 + 2) vs. (G3 + 4)	0.416	0.64 (0.22-1.88)	0.257	0.53 (0.18-1.59)	0.305	0.45 (0.10-2.06)	0.094	0.28 (0.06-1.24)
By postoperative treatment Untreated vs. treated	0.064	2.37 (0.95-5.93)	0.447	1.40 (0.59-3.29)	0.723	1.22 (0.41-3.57)	0.483	1.39 (0.55-3.49)

The P-values, hazard ratios (HR) and 95% confidence intervals (CI) of different parameters concerning MFS were calculated using Cox regression analyses. The analysis was performed separately for each factor with the parameters listed in the table being introduced as covariates, respectively.

ISSN: 1476-4598